The neutralizing antibody response against West Nile virus in naturally infected horses.

The neutralizing antibody response against West Nile virus in naturally infected horses. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The neutralizing antibody response against West Nile virus in naturally infected horses. Abstract Text:

Melissa D ,Theodore C Pierson,Marciela M Degrace,Lisa M Mattei,Sheri L Hanna,Fabio Del Piero,Robert W Doms,

A major neutralizing epitope (here referred to as the T332 epitope) located on the lateral surface of domain III (DIII) of the West Nile virus (WNV) envelope protein has been identified based on the analysis of murine monoclonal antibodies. However, little is known about the humoral immune response against WNV in a natural host or whether DIII in general or the T332 epitope in particular are important targets of neutralizing antibodies in vivo. To characterize the types of antibodies produced during infection with WNV, we studied a group of naturally infected horses. Using immune adsorption assays coupled with the use of virus particles bearing mutations in the T332 epitope, we found that in some animals neutralizing activity against DIII and the T332 epitope was below the limit of detection. In contrast, some animals generated a significant fraction of neutralizing activity to DIII and the T332 epitope. Thus, while antibodies to the T332 epitope did not represent a significant fraction of the total antibody response in the infected animals studied, in some horses, they comprised a significant fraction of neutralizing activity, making this an important but far from dominant neutralizing epitope. Rather, the neutralizing response to WNV generated in infected horses is both variable and polyclonal in nature, with epitopes within and outside of DIII playing important roles.

The neutralizing antibody response against West Nile virus in naturally infected horses. Publishing Authors By Initials

MD ,TC Pierson,MM Degrace,LM Mattei,SL Hanna,F Del Piero,RW Doms,

For similar virus diseases: arbovirus infections: encephalitis, arbovirus: west nile fever research abstracts see: virus diseases: arbovirus infections: encephalitis, arbovirus: west nile fever research

PUBMED ID PMID:

MEDLINE DATE:

The neutralizing antibody response against West Nile virus in naturally infected horses. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Virology

VOLUME: 359

Page Numbers: 336-48

Journal Abbreviation: Virology

ISSN: 0042-6822

DAY: 20

MONTH: 10

YEAR: 2006

The neutralizing antibody response against West Nile virus in naturally infected horses. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 110674

The neutralizing antibody response against West Nile virus in naturally infected horses. Keywords Mesh Terms:

KEYWORDS: West Nile Fever

MESH TERMS: veterinary

Chemical & Substance for Abstract: The neutralizing antibody response against West Nile virus in naturally infected horses. Information

Substance Name: Viral Envelope Proteins

Registry Number: 0

Grant and Affiliation Information for The neutralizing antibody response against West Nile virus in naturally infected horses.

AFFILIATION: Department of Microbiology, University of Pennsylvania, 225 Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, USA.

Country: United States

AGENCY: United States PHS

GRANT: U54 457173

ACRONYM: AI

MEDLINETA: Virology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The neutralizing antibody response against West Nile virus in naturally infected horses Related Publications

• Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
• Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein.
• The neutralizing antibody response against West Nile virus in naturally infected horses.
• V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.